ANA-HEp2 pattern evaluation in pancreatic cancer:What can the autoantibodies tell us?  

作　　者：Amanda PB Albuquerque Amanda R Fernandes Angela LBP Duarte Henrique de Ataide Mariz José GCA Júnior Luiz A Mattos Maira Galdino da Rocha Pitta Moacyr JBM Rego 

机构地区：[1]Laboratory of Immunomodulation and New Therapeutical Approaches,Research Centre for Therapeutic Innovation Suely Galdino(NUPIT-SG),Federal University of Pernambuco,Recife,PE,Brazil [2]Rheumatology Service,Hospital das Clínicas,Recife,PE,Brazil [3]General Surgery Service,Hospital das Clínicas,Recife,PE,Brazil [4]Oncology Service,Hospital das Clínicas,Recife,PE,Brazil

出　　处：《Hepatobiliary & Pancreatic Diseases International》2023年第1期104-106,共3页国际肝胆胰疾病杂志（英文版）

基　　金：supported by grants from the Brazilian government research foundation:Coordenacao de Aperfeicoamento de Pessoal de Nível Superior(CAPES);Conselho Nacional de Desenvolvimento Científico e Tecnológico(312981/2018-0);the Sociedade Brasileira de Reumatologia(on behalf of Dr.Angela LBP Duarte)。

摘　　要：To the Editor:Pancreatic neoplasms are mainly diagnosed by imaging methods and confirmed by biopsies[1].Imaging techniques and the tumor markers carbohydrate antigen 19-9(CA19-9)or carcinoembryonic antigen(CEA)used for follow-up,are expensive and of low sensitivity and specificity[2].

关 键 词：NEOPLASMS PATTERN SPECIFICITY 

分 类 号：R735.9[医药卫生—肿瘤]